Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy

Antiviral Research

Volumn 126, Issue , 2016, Pages 90-98

  De Silva Feelixge, Harshana S ^a   Stone, Daniel ^a   Pietz, Harlan L ^a,b,c,d   Roychoudhury, Pavitra ^a   Greninger, Alex L ^b   Schiffer, Joshua T ^a,b   Aubert, Martine ^a   Jerome, Keith R ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Endonuclease; Resistance; Reverse transcriptase; Zinc finger nuclease

Indexed keywords

AMINO ACID; CD4 ANTIGEN; EXONUCLEASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; INTEGRASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZINC FINGER NUCLEASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ENDONUCLEASE; EXODEOXYRIBONUCLEASE; PHOSPHOPROTEIN; POL PROTEIN; TREX2 PROTEIN, HUMAN; VIRUS DNA; ZINC FINGER PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; GENE DISRUPTION; GENE INSERTION; GENOME DIRECTED ANTIVIRAL ENDONUCLEASE THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS INHIBITION; VIRUS MUTANT; ANTIVIRAL RESISTANCE; CELL LINE; DRUG EFFECTS; GENETIC TRANSDUCTION; GENETICS; HEK293 CELL LINE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; VIROLOGY; VIRUS REPLICATION;

ANTI-HIV AGENTS; BASE SEQUENCE; CELL LINE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; ENDONUCLEASES; EXODEOXYRIBONUCLEASES; GENE PRODUCTS, POL; HEK293 CELLS; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHOPROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; TRANSDUCTION, GENETIC; VIRUS REPLICATION; ZINC FINGERS;

EID: 84953225653     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.12.007     Document Type: Article

References (58)

1. A. Adachi, and et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone J. Virol. 59 2 1986 284 291
2. J.L. Andersen, and et al. HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT PLoS Pathog. 2 12 2006 e127
3. M. Aubert, and et al. Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI PloS One 6 2 2011 e16825
4. M. Aubert, and et al. In vitro inactivation of latent HSV by targeted mutagenesis using an HSV-specific homing endonuclease Mol. Ther. Nucleic acids 3 2014 e146
5. K. Bloom, and et al. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases Mol. Ther. J. Am. Soc. Gene Ther. 21 10 2013 1889 1897
6. C.A. Boucher, and et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects J. Infect. Dis. 165 1 1992 105 110
7. F. Ceccherini-Silberstein, and et al. High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations J. Virol. 79 16 2005 10718 10729
8. J. Chen, and et al. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases Mol. Ther. J. Am. Soc. Gene Ther. 22 2 2014 303 311
9. W. Ding, and et al. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 20 24 2014 6495 6503
10. H. Ebina, and et al. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus Sci. Rep. 3 2013 2510
11. H. Ebina, and et al. A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector PLoS One 10 3 2015 e0120047
12. H.M. Elbadawy, and et al. Gene transfer of integration defective anti-HSV-1 meganuclease to human corneas ex vivo Gene Ther. 21 3 2014 272 281
13. T. Gaj, C.A. Gersbach, and C.F. Barbas 3rd ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering Trends Biotechnol. 31 7 2013 397 405
14. D. Glebe, and A. Geipel Selected phenotypic assays used to evaluate antiviral resistance and viral fitness of hepatitis B virus and its variants Intervirology 57 3-4 2014 225 231
15. F.L. Graham, and et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5 J. Gen. Virol. 36 1 1977 59 74
16. S. Grosse, and et al. Meganuclease-mediated inhibition of HSV1 infection in cultured cells Mol. Ther. J. Am. Soc. Gene Ther. 19 4 2011 694 702
17. M. Hafez, and G. Hausner Homing endonucleases: DNA scissors on a mission Genome/National Res. Counc. Can.=Genome/Conseil National de Recherches Canada 55 8 2012 553 569
18. P.R. Harrigan, S. Bloor, and B.A. Larder Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro J. Virol. 72 5 1998 3773 3778
19. Z. Hu, and et al. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy J. Clin. Invest. 125 1 2015 425 436
20. Z. Hu, and et al. Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells BioMed Res. Int. 2014 2014 612823
21. W. Hu, and et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection Proc. Natl. Acad. Sci. U. S. A. 111 31 2014 11461 11466
22. J. Karpinski, and et al. Universal Tre (uTre) recombinase specifically targets the majority of HIV-1 isolates J. Int. AIDS Soc. 17 4 Suppl. 3 2014 19706
23. P. Kellam, and et al. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance J. Gen. Virol. 75 Pt 2 1994 341 351
24. E.M. Kennedy, and et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease Virology 476C 2014 196 205
25. E.M. Kennedy, and et al. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease J. Virol. 88 20 2014 11965 11972
26. H.K. Liao, and et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells Nat. Commun. 6 2015 6413
27. S.R. Lin, and et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo Mol. Ther. Nucleic Acids 3 2014 e186
28. M.L. Maeder, and et al. Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification Mol. Cell 31 2 2008 294 301
29. N. Manjunath, and et al. Newer gene editing technologies toward HIV gene therapy Viruses 5 11 2013 2748 2766
30. T. Mino, and et al. Gene- and protein-delivered zinc finger-staphylococcal nuclease hybrid for inhibition of DNA replication of human papillomavirus PloS One 8 2 2013 e56633
31. T. Mino, and et al. Inhibition of DNA replication of human papillomavirus by using zinc finger-single-chain FokI Dimer hybrid Mol. Biotechnol. 56 8 2014 731 737
32. E. Nowak, and et al. Ty3 reverse transcriptase complexed with an RNA-DNA hybrid shows structural and functional asymmetry Nat. Struct. Mol. Biol. 21 4 2014 389 396
33. V. Pattanayak, J.P. Guilinger, and D.R. Liu Determining the specificities of TALENs, Cas9, and other genome-editing enzymes Methods Enzym. 546 2014 47 78
34. J.M. Pawlotsky New hepatitis C therapies: the toolbox, strategies, and challenges Gastroenterology 146 5 2014 1176 1192
35. Q.D. Pham, and et al. Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis AIDS 28 18 2014 2751 2762
36. J. Piret, and G. Boivin Antiviral drug resistance in herpesviruses other than cytomegalovirus Rev. Med. Virol. 24 3 2014 186 218
37. A.A. Price, and et al. Cas9-mediated targeting of viral RNA in eukaryotic cells Proc. Natl. Acad. Sci. U. S. A. 112 19 2015 6164 6169
38. X. Qu, and et al. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells Nucleic Acids Res. 41 16 2013 7771 7782
39. X. Qu, and et al. Zinc finger nuclease: a new approach for excising HIV-1 proviral DNA from infected human T cells Mol. Biol. Rep. 41 9 2014 5819 5827
40. J.D. Sander, M.L. Maeder, and J.K. Joung Engineering designer nucleases with customized cleavage specificities Frederick M. Ausubel, Current Protocols in Molecular Biology 2011 (Chapter 12): p. Unit12 13
41. I. Sarkar, and et al. HIV-1 proviral DNA excision using an evolved recombinase Science 316 5833 2007 1912 1915
42. B.D. Sather, and et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template Sci. Transl. Med. 7 307 2015 307ra156
43. J.T. Schiffer, and et al. Targeted DNA mutagenesis for the cure of chronic viral infections J. Virol. 86 17 2012 8920 8936
44. J.T. Schiffer, and et al. Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach PLoS Comput. Biol. 9 7 2013 e1003131
45. C. Seeger, and J.A. Sohn Targeting hepatitis B virus with CRISPR/Cas9 Mol. Ther. Nucleic Acids 3 2014 e216
46. D. Stone, H.P. Kiem, and K.R. Jerome Targeted gene disruption to cure HIV Curr. Opin. HIV AIDS 8 3 2013 217 223
47. A. Tanaka, and et al. A novel therapeutic molecule against HTLV-1 infection targeting provirus Leukemia 27 8 2013 1621 1627
48. J. Wang, and S.R. Quake RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection Proc. Natl. Acad. Sci. U. S. A. 111 36 2014 13157 13162
49. N.D. Weber, and et al. DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward Virology 454-455 2014 353 361
50. N.D. Weber, and et al. AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication PloS One 9 5 2014 e97579
51. X. Wei, and et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy Antimicrob. Agents Chemother. 46 6 2002 1896 1905
52. S.E. Wirt, and M.H. Porteus Development of nuclease-mediated site-specific genome modification Curr. Opin. Immunol. 24 5 2012 609 616
53. H.S. Wollebo, and et al. CRISPR/Cas9 system as an agent for eliminating polyomavirus JC infection PloS One 10 0 2015 e0136046
54. L. Yu, and et al. Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells OncoTargets Ther. 8 2015 37 44
55. K.S. Yuen, and et al. CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells J. Gen. Virol. 96 Pt 3 2015 626 636
56. S. Zhen, and et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9 Biochem. Biophys. Res. Commun. 450 4 2014 1422 1426
57. S. Zhen, and et al. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus Gene Ther. 22 5 2015 404 412
58. W. Zhu, and et al. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA Retrovirology 12 1 2015 22